Skip to main content
SpringerLink
Log in

Immunostaining for proliferating cell nuclear antigen: its role in determination of proliferation in routinely processed human brain tumor specimens

  • Regular Papers
  • Published:
Acta Neuropathologica Aims and scope Submit manuscript

Abstract

Alcohol- and formalin-fixed, paraffin-embedded samples of 71 brain tumors (35 gliomas, 22 metastatic carcinomas, 8 meningiomas and 6 other tumors) were investigated by immunocytochemistry with three different monoclonal antibodies against proliferating cell nuclear antigen (PCNA)/cyclin (19A2; 19F4; PC10). PC10 was found to work best; it is applicable to both alcohol- and formalin-fixed tumor samples. PCNA labeling indices (LIs) were compared in the same tumors with LIs obtained by Ki-67 immunostaining of frozen sections and by in vitro incubation with bromodeoxyuridine (BrdUrd); in the latter preparations, BrdUrd LIs could be compared with PCNA LIs in the very same areas of serial sections. In gliomas, PCNA LIs were 0.7–80.2% (mean 31.7%), in metastases 0–76.0% (mean 47.8%), and in meningiomas 0–53.0% (mean 19.3%). In general, PCNA LIs were highly significantly correlated with Ki-67 LIs (P=0.0002) and BrdUrd LIs (P=0.0001). However, when tumor subgroups are considered, only gliomas show a significant correlation with Ki-67 and BrdUrd LIs. Despite this statistical correlation, PCNA expression was out of proportion to proliferation indices as determined by both other methods in almost one third of all brain tumors. Immunocytochemistry for PCNA produces a broad spectrum of staining intensity of labeled nuclei, whose number is dependent upon the sensitivity of the immunocytochemical technique used. Thus, inter-oberserver and inter-laboratory variabilities in PCNA LI determination may occur. Overlapping of PCNA LIs between tumor subgroups of varying malignancy further limits the informational value for the individual case. In some classic meningiomas, high PCNA scores do not reflect the proliferative activity of the tumor, as Ki-67 and BrdUrd LIs are very low in these cases. We conclude that PCNA immunolabeling is of limited value in the individual tumor, mainly due to overexpression in many tumors, and at present cannot be recommended to replace Ki-67 and/or BrdUrd labeling methods for routine determination of proliferative activity in human tumor specimens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Allegranza A, Girlando S, Arrigoni GL, Veronese S, Mauri FA, Gambacorta M, Pollo B, Dalla Palma P, Barbareschi M (1991) Proliferating cell nuclear antigen expression in central nervous system neoplasms. Virchows Arch [A] 419: 417–423

    Google Scholar 

  2. Bauer GA, Burgers PM (1988) The yeast analog of mammalian cyclin/proliferating cell nuclear antigen interacts with mammalian DNA polymerase delta. Proc Natl Acad Sci USA 85: 7506–7510

    Google Scholar 

  3. Benjamin DR, Gown AM (1991) Aberrant cytoplasmic expression of proliferating cell nuclear antigen in Hodgkin's disease. Am J Surg Pathol 15: 764–768

    Google Scholar 

  4. Bravo R (1986) Synthesis of the nuclear protein cyclin (PCNA) and its relationship with DNA replication. Exp Cell Res 163: 287–293

    Google Scholar 

  5. Bravo R, Macdonald-Bravo H (1987) Existance of two populations of cyclin/PCNA during the cell cycle: association with DNA replication sites. J Cell Biol 105: 1549–1554

    Google Scholar 

  6. Bravo R, Frank R, Blundell PA, MacDonald-Bravo H (1987) Cyclin/PCNA is the auxiliary protein of DNA polymerase-δ. Nature 326: 515–517

    Google Scholar 

  7. Burns DK, Mickey BE, Bigio EH, White CL (1992) Proliferating cell nuclear antigen (PCNA) expression in human gliomas and meningiomas (abstract). J Neuropathol Exp Neurol 51: 362

    Google Scholar 

  8. Celis JE, Celis A (1985) Cell cycle-dependent variation in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci USA 82: 3262–3266

    Google Scholar 

  9. Dalla Palma P, Barbareschi M, Perrone G, Mauri FA, Girlando S, Leonardi E, Togni R, Boi S, Dvornik G (1991) PCNA and Ki-67 expression in breast carcinomas (abstract). Pathol Res Pract 187: 674

    Google Scholar 

  10. Dervan PA, Magee HM, Buckley C, Carney DN (1992) Proliferating cell nuclear antigen counts in formalin-fixed paraffin-embedded tissue correlate with Ki-67 in fresh tissue. Am J Clin Pathol 97 [Suppl 1]: S21-S28

    Google Scholar 

  11. Dierendonk JH van, Wijsman JH, Keijzer R, van de Velde CJH, Cornelisse CJ (1991) Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Am J Pathol 138: 1165–1172

    Google Scholar 

  12. Galand P, Degraef C (1989) Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labeling for marking S phase cells in paraffin sections from animal and human tissues. Cell Tissue Kinet 22: 383–392

    Google Scholar 

  13. Garcia RL, Coltrera MD, Gown AM (1989) Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Am J Pathol 134: 733–739

    Google Scholar 

  14. Golick ML, Rice M (1992) Optimum staining of PCNA in paraffin sections is dependent on fixation, dyring, and intensification. J Histotechnol 15: 39–41

    Google Scholar 

  15. Hall PA, Levison DA, Woods AL, Yu CC-W, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Campleijohn R, Dover R, Waseem NH, Lane DP (1990) Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasmas. J Pathol 162: 285–294

    Google Scholar 

  16. Hsu S-M, Raine L, Fanger H (1981) Use of avidin-biotinperoxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577–580

    Google Scholar 

  17. Jaskulski D, DeRiel JK, Mercer WE, Calabretta B, Baserga R (1988) Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA Cyclin. Science 240: 1544–1546

    Google Scholar 

  18. Kurki P, Lotz M, Ogata K, Tan EM (1987) Proliferating cell nuclear antigen (PCNA)/cyclin in activated human T lymphocytes. J Immunol 138: 4114–4120

    Google Scholar 

  19. Kurki P, Ogata K, Tan EM (1988) Monoclonal antibodies to proliferating cell nuclear antigen (PCNA)/cyclin as probes for proliferating cells by immunofluorescence microscopy and flow cytometry. J Immunol Methods 109: 49–59

    Google Scholar 

  20. Louis DN, Edgerton S, Thor AD, Hedley-Whyte ET (1991) Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study. Acta Neuropathol 81: 675–679

    Google Scholar 

  21. Maier H, Morimura T, Öfner D, Hallbrucker C, Budka H (1990) Argyrophilic nucleolar organizer region proteins (AgNORs) in human brain tumors: relations with malignancy and proliferation indices. Acta Neuropathol 80: 156–162

    Google Scholar 

  22. Maier H, Kitz K, Öfner D, Hittmair A, Budka H (1992) Classical, atypical and anaplastic meningioma: three histopathological subtypes of clinical relevance. J Neurosurg 77: 616–623

    Google Scholar 

  23. Mathews MB, Bernstein RM, Franza BR Jr, Garrels GI (1984) Identity of the proliferating cell nuclear antigens and cyclin. Nature 309: 374–376

    Google Scholar 

  24. Mauri FA, Allegranza A, Barbareschi M, Girlando S, Pollo B, Palma P, Scampinis S (1991) PCNA expression in pleomorphic astrocytomas and in other glial neoplasms (abstract). Pathol Res Pract 187: 723

    Google Scholar 

  25. Morimura T, Kitz K, Budka H (1989) In situ analysis of cell kinetics in brain tumors. Acta Neuropathol 77: 276–282

    Google Scholar 

  26. Morimura T, Kitz K, Stein H, Budka H (1991) Determination of proliferative activities in human brain tumor specimens: a comparison of three methods. J Neuro-Oncol 10: 1–11

    Google Scholar 

  27. Morris GF, Mathews MB (1989) Regulation of proliferating cell nuclear antigen during cell cycle. J Biol Chem 264: 13 856–13 864

    Google Scholar 

  28. Ogata K, Kurki P, Celis J, Nakamura RM, Tan EM (1987) Monoclonal antibodies to a nuclear protein (PCNA, cyclin) associated with DNA replication. Exp Cell Res 168: 475–486

    Google Scholar 

  29. Pelosi G, Zamboni G, Colombari R, Castelli P, Pea M, Bresaola E, Boneti F, Iannucci A (1991) Immunohistochemical detection of proliferating cell nuclear antigen (PCNA) in P.E.T. (pancreatic endocrine tumors) (abstract). Pathol Res Pract 198: 744

    Google Scholar 

  30. Prelich G, Kostura M, Marshak DR, Mathews MB, Stillman B (1987) The cell-cycle regulated proliferating cell nuclear antigen is required for SV40 DNA replication in vitro. Nature 326: 471–475

    Google Scholar 

  31. Prelich G, Tan C-K, Kostura M, Mathews MB, So AG, Downey KM, Stillman B (1987) Functional identity of proliferating cell nuclear antigen and a DNA polymerase-delta auxiliary protein. Nature 326: 517–520

    Google Scholar 

  32. Robbins BA, de la Vega D, Ogata K, Tan EM, Nakamura RM (1987) Immunohistochemical detection of proliferating cell nuclear antigen in solid human malignancies. Arch Pathol Lab Med 111: 841–845

    Google Scholar 

  33. Smetana K, Gyorkey F, Chan P-K, Tan E, Busch H (1983) Proliferating cell nuclear antigen (PCNA) and human malignant tumor nucleolar antigens (HMTNA) in nucleoli of human hematological malignancies. Blut 46: 133–141

    Google Scholar 

  34. Tan CK, Sullivan K, Li XY, Tan EM, Downey KM, So AG (1987) Autoantibody to the proliferating cell nuclear antigen neutralizes the activity of the auxiliary protein for polymerase delta. Nucleic Acids Res 15: 9299–9308

    Google Scholar 

  35. Waseem NH, Lane DP (1990) Monoclonal antibody analysis of proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci 96: 121–129

    Google Scholar 

Download references

Author information

Author notes

  1. T. Morimura

    Present address: Department of Neurosurgery, Hyogo College of Medicine, Nishinomiya, Japan

Authors and Affiliations

  1. Clinical Department for Neuropathology and Neurochemistry, Neurological Institute, Neues AKH, Währinger Gürtel 18-20, A-1090, Vienna, Austria

    S. Khoshyomn, H. Maier, T. Morimura & H. Budka

  2. Neurosurgical Clinic, University of Vienna, Austria

    K. Kitz

Authors
  1. S. Khoshyomn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Maier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Morimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Kitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Budka
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported in part by a grant from the Oncology Commission, Medical Faculty, University of Vienna

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khoshyomn, S., Maier, H., Morimura, T. et al. Immunostaining for proliferating cell nuclear antigen: its role in determination of proliferation in routinely processed human brain tumor specimens. Acta Neuropathol 86, 582–589 (1993). https://doi.org/10.1007/BF00294296

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00294296

Key words

Search

Navigation